Phase I trial design for drug combinations with Bayesian model averaging-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase I trial design for drug combinations with Bayesian model averaging

Published:2015-01-13 Issue:2 Volume:14 Page:108-119
ISSN:1539-1604
Container-title:Pharmaceutical Statistics
language:en
Short-container-title:Pharmaceut. Statist.

Author:

Jin Ick Hoon¹,Huo Lin²,Yin Guosheng³,Yuan Ying⁴

Affiliation:

1. Center for Biostatistics; The Ohio State University Wexner Medical Center; Columbus OH 43221 USA

2. Novartis Pharmaceuticals Corporation; East Hanover NJ 07936 USA

3. Department of Statistics and Actuarial Science; The University of Hong Kong; Hong Kong

4. Department of Biostatistics; The University of Texas M.D. Anderson Cancer Center; Houston TX 77030 USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology,Statistics and Probability

Reference28 articles.

1. Cancer phase I clinical trials: efficient dose escalation with overdose control;Babb;Statistics in Medicine,1998

2. A random walk rule for phase I clinical trials;Durham;Biometrics,1997

3. Some practical improvements in the continual reassessment method for phase I studies;Goodman;Statistics in Medicine,1995

4. Bayesian optimal designs for phase I clinical trials;Haines;Biometrics,2003

5. An extension of the continual reassessment method using decision theory;Leung;Statistics in Medicine,2002

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of toxicities related to novel therapy in clinical trials for women with gynecologic cancer;Cancer;2020-02-25

2. A New Bayesian Dose-Finding Design for Drug Combination Trials;Statistics in Biopharmaceutical Research;2017-10-02

3. Estimation of QT interval prolongation through model-averaging;Journal of Pharmacokinetics and Pharmacodynamics;2017-04-18

4. Hyperbaric oxygen brain injury treatment (HOBIT) trial: a multifactor design with response adaptive randomization and longitudinal modeling;Pharmaceutical Statistics;2016-06-15

5. Identifying a maximum tolerated contour in two-dimensional dose finding;Statistics in Medicine;2016-02-22

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3